- Home
- OSRH vs CVKD Comparison
OSRH vs CVKD Comparison
Compare OSRH & CVKD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | OSRH | CVKD |
|---|---|---|
| Founded | N/A | 2022 |
| Country | United States | United States |
| Employees | 21 | N/A |
| Industry | | Medicinal Chemicals and Botanical Products |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 11.7M | 9.9M |
| IPO Year | N/A | 2022 |
Fundamental Metrics
Financial Performance| Metric | OSRH | CVKD |
|---|---|---|
| Price | $0.59 | $5.41 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 1 |
| Target Price | N/A | ★ $13.00 |
| AVG Volume (30 Days) | ★ 720.1K | 43.3K |
| Earning Date | 05-19-2026 | 05-08-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 23.94 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $9.30 | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $0.38 | $4.21 |
| 52 Week High | $1.79 | $17.50 |
Technical Indicators
Market Signals| Indicator | OSRH | CVKD |
|---|---|---|
| Relative Strength Index (RSI) | 62.18 | 48.85 |
| Support Level | $0.54 | $5.13 |
| Resistance Level | $0.60 | $14.30 |
| Average True Range (ATR) | 0.05 | 0.52 |
| MACD | 0.01 | 0.18 |
| Stochastic Oscillator | 80.51 | 64.32 |
Price Performance
Historical ComparisonAbout OSRH OSR Holdings Inc.
OSR Holdings Inc is a healthcare company dedicated to healthcare outcomes and improving the quality of life for people and their families. It builds and develops a robust portfolio of potentially transformative therapies and healthcare solutions. The business of the company includes developing oral immunotherapies for the treatment of cancer, developing design-augmented biologics for age-related and other degenerative diseases, and neurovascular intervention medical device and systems distribution in Korea.
About CVKD Cadrenal Therapeutics Inc.
Cadrenal Therapeutics Inc is developing tecarfarin, its drug candidate, for unmet needs in anticoagulation therapy. Tecarfarin is a late-stage novel oral and reversible anticoagulant (blood thinner) designed to prevent heart attacks, strokes, and deaths due to blood clots in patients with rare cardiovascular conditions requiring chronic anticoagulation.